AstraZeneca rookies vs. Roche and Alexion

Read: Two years after the split from AstraZeneca, the FDA approved up for its first innovative drug, UplinzaTwo years after theAstraZeneca subsidiary Viela Bio went on the market, its anti-CD19 monoclonal antibody Uplizna (inebilizumab-cdon) recently received FDA approval for the treatment of patients with the optic neurospinal corditis spectrum disease (NMOSD), which has been approved by the FDA for breakthrough treatment and orphan drug qualificationthis is the first FDA-approved innovation treatment since Viela Bio's inception, and the second to date to receive FDA-approved treatment for such patients, which Viela is expected to launch this month, according to Evaluate's data analysis, the drug could generate sales of $586 million in 2026But for now, NMOSD's competitive landscape could challenge the initial listing of AZ's subsidiaryfront-facing rivals - Roche Rituxan and its biosimilars
Uplinza and Roche's Rituxan are B-cell consumers, and doctors may choose to use Rituxan or their biosimilars before Uplinzadata show that meronial sales of 7.3 billion Swiss francs in 2016, 7.388 billion Swiss francs in 2017 and ChF6,752 million in 2018, is one of Roche's heavyweightspatent protection in Europe for lituxere expired at the end of 2014 and in the United States in 2018As of 2018, there are about 27 Melohua biosimilars under development worldwidedrug data, four biosimilar drugs have been approved worldwide, including Hanlikang, which has been approved by China's Fuhong Han-Ho, of which Truxima of Celltrion and Rixathon/Riximyo of Novartis have been approved for listing in the European UnionOn November 28, 2018, the FDA also approved the CT-P10 jointly developed by Celltrion/Tevaat present, the litoxim-bifida injection spent in the domestic Cinda biodevelopment through the priority review approval process is in the CDE in the review statusIn addition, Haizheng Pharmaceuticals, Zhengda Tianqing, Hualan Biology, Lizhu Monodyagain and other enterprises are also actively developing and registering similar drugs in the United Statesupgrade rival, Alexion's Soliris, experts believe that Uplinza and Rituxan are B-cell consumers, and if the effect is limited, doctors may choose to try Alexion's Soliris instead of continuing to use Uplinza or Rituxan and its similar drugs Soliris is a pioneering complement inhibitor that works by inhibiting the C5 protein in the end part of the complement cascade reaction Complementary cascade reactions are part of the immune system and their uncontrolled activation plays an important role in severe rare and super-rare diseases Soliris was approved for treatment of Patients with Anti-AQP4 Antibody-positive NMOSD in the United States, the European Union and Japan in June, August and November 2019, respectively, and has been granted orphan drug qualification (ODD) for patients with NMOSD In addition, the drug is the first drug approved in the United States and Europe to treat NMOSD Soliris is currently approved for indications: burstsleep hemoglobinuria (PNH), atypical hemolytic uremia syndrome (aHUS), anti-acetylcholine receptor (AchR) antibody-positive severe muscle weakness (MG) and NMOSD, is a very important product of Alexion, contributing to nearly 90% of the company's sales In the face of its patent expiration, Alexion is working tirelessly to build an upgraded version of Soliris Ultomiris, the world's first long-acting C5 inhibitor, is currently undergoing phase III testing potential rivals - Rochesatralizumab Roche's Satralizumab is a humanized IgG2 monotophosis using SMART recycling technology, targeting IL-6 receptors, regulating multiple stages of NMOSD disease, such as inhibition of NMOSD-specific antibody AQP4-IgG and inflammatory reactions in the central nervous system , Roche has submitted a listing application for Satralizumab in 13 countries and regions around the world, including China , Satralizumab received the FDA Breakthrough Therapy Certification (BTD) in December 2018 and filed for listing in August 2019 In addition, satralizumab was certified as an orphan drug by the European Medicines Agency (EMA) in June 2016 and submitted a listing application in August 2019 Satralizumab's application for listing in Japan was submitted in November 2019 and was certified and qualified for priority review of orphan medicine On May 15 this year, the State Drug Administration (NMPA) officially accepted the application for a listing of the rare disease dispaneural spinal cord itise lineage disease (NMOSD) treatment drug satralizumab conclusion: AstraZeneca subsidiary Viela Bio's first innovative drug Uplinza, the market after the face of Roche's heavy-weight products, Roche's heavyweight new drug and Alexion's ace drug and its upgraded drug, the two giants under the multiple clampdown, HOW can AZ break into the market? Will robbing market resources turn into a price war? Let's wait and see, and look forward to benefiting more patients in the healthy market competition